1. Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease
- Author
-
Yvette A. M. Grimbergen, Lotte van de Wiel, Raymund A.C. Roos, Jeroen van der Grond, Huub A. M. Middelkoop, Caroline K. Jurgens, Marie-Noëlle W. Witjes-Ané, and Ad C. G. M. van Es
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Heterozygote ,Neurology ,Caudate nucleus ,Motor Activity ,Neuropsychological Tests ,Basal Ganglia ,Cognition ,Huntington's disease ,Thalamus ,Trinucleotide Repeats ,Basal ganglia ,medicine ,Humans ,Psychomotor learning ,Psychomotor function ,Putamen ,Organ Size ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Globus pallidus ,Huntington Disease ,nervous system ,Female ,Neurology (clinical) ,Psychology - Abstract
To establish differences in basal ganglia and thalamic volume between preclinical carriers and non-carriers of the Huntington’s disease (HD) gene and to link the volume to motor, cognitive and behavioural characteristics in carriers. Sixteen HD gene carriers without overt clinical motor signs and 14 non-gene carriers underwent clinical evaluation and a MRI scan. Volumes of the caudate nucleus, putamen, gobus pallidus and thalamus were measured using T1-weighted MR images. Motor, cognitive and behavioural functioning was assessed using the Unified Huntington’s Disease Rating Scale (UHDRS), cognitive testing and the Beck Depression Inventory (BDI-II). Volumes of the caudate nucleus, putamen and globus pallidus were significantly smaller in carriers than in non-carriers while no differences between groups were found on clinical evaluation. In gene carriers smaller globus pallidus volume was associated with more motor abnormalities. A smaller putamen volume correlated significantly with worse psychomotor function on the Symbol Digit Modalities Task and the Trail Making Test B. In line with previous research we demonstrated that basal ganglia abnormalities precede overt disease manifestation of HD. Besides we showed that smaller basal ganglia volumes are related to subtle motor abnormalities and worse psychomotor performance in gene carriers without clinical diagnosis. Motor and psychomotor measures may be suitable clinical markers in future neuroprotective trials when combined with volumetric imaging.
- Published
- 2008